Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study
- PMID: 37642764
- DOI: 10.1007/s10067-023-06744-z
Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study
Abstract
Objectives: The aim of this study was to investigate the relation among atherosclerosis, antibodies against oxidized LDL (anti-oxLDL), and inflammation in rheumatoid arthritis (RA) patients treated with biological (b) disease-modifying anti-rheumatic drugs (DMARDs).
Methods: Fifty-nine patients who were receiving conventional synthetic DMARDs and were eligible for treatment with a biological agent were included in the study. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and IgG antibodies against oxidized LDL (anti-oxLDL) as well as carotid intima-media thickness (cIMT) were determined before and after 6 months of treatment. Thirty-one healthy individuals were used as a control group.
Results: At baseline, RA patients had lower TC and HDL-C levels and increased cIMT compared to controls. After a 6-month follow-up, the re-evaluation of carotids revealed a statistically important decrease of cIMT values. This observation was accompanied by a statistically important elevation of HDL-C levels and a reduction of the titer of anti-oxLDL antibodies regardless of the bDMARD that was administered. No statistically significant association was found between the cIMT and anti-oxLDL, HDL-C, CRP, or DAS28 score neither before nor 6 months after treatment using linear regression analyses adjusted for age and gender.
Conclusions: We provide evidence that atherogenic lipid profile and ongoing atherosclerosis which characterize RA patients appear to improve after biological therapy, and we also suggest a possible atherogenic effect of IgG anti-ox LDL antibodies.
Keywords: Antibodies against oxidized LDL atherosclerosis; Biologic agents; Cardiovascular risk; Intima-media thickness; Rheumatoid arthritis.
© 2023. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Similar articles
-
The effects of biologic agents on cardiovascular risk factors and atherosclerosis in rheumatoid arthritis patients: a prospective observational study.Heart Vessels. 2022 Dec;37(12):2128-2136. doi: 10.1007/s00380-022-02114-y. Epub 2022 Jun 24. Heart Vessels. 2022. PMID: 35739432
-
The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis.J Korean Med Sci. 2016 Feb;31(2):202-7. doi: 10.3346/jkms.2016.31.2.202. Epub 2016 Jan 14. J Korean Med Sci. 2016. PMID: 26839473 Free PMC article.
-
Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy.Scand J Rheumatol. 2006 Mar-Apr;35(2):107-11. doi: 10.1080/03009740500474578. Scand J Rheumatol. 2006. PMID: 16641043
-
Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.Clin Exp Rheumatol. 2009 May-Jun;27(3):446-51. Clin Exp Rheumatol. 2009. PMID: 19604437 Review.
-
The impact of biologic agents on cardiovascular risk factors in patients with rheumatoid arthritis: A meta analysis.PLoS One. 2024 Aug 29;19(8):e0306513. doi: 10.1371/journal.pone.0306513. eCollection 2024. PLoS One. 2024. PMID: 39208032 Free PMC article.
Cited by
-
Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There a Common Basis?Life (Basel). 2024 May 31;14(6):716. doi: 10.3390/life14060716. Life (Basel). 2024. PMID: 38929699 Free PMC article. Review.
References
-
- Venetsanopoulou AI, Alamanos Y, Voulgari PV, Drosos AA (2022) Epidemiology of rheumatoid arthritis: genetic and environmental influences. Expert Rev Clin Immunol 18(9):923–931 - PubMed
-
- Blum A, Adawi M (2019) Rheumatoid arthritis (RA) and cardiovascular disease. Autoimmun Rev 18(7):679–690 - PubMed
-
- Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317–325 - PubMed
-
- Björkbacka H, Fredrikson GN, Nilsson J (2013) Emerging biomarkers and intervention targets for immune-modulation of atherosclerosis - a review of the experimental evidence. Atherosclerosis 227:9–17 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous